~~<i id='9A1A6C9D8B'><strike id='9A1A6C9D8B'><tt id='9A1A6C9D8B'><pre id='9A1A6C9D8B'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：explore 2025-10-04 09:11:41 Page View：27

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Free speech concerns arise in wake of journal editor Eisen's firing
Next article： Trump demands the U.S. pay no more for drugs than other countries … again

explore

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Flagship Pioneering startup Sonata Therapeutics lays off 21

AdobeSonataTherapeutics,astartupcreatedtwoyearsagothroughthemergeroftwoFlagshipPioneeringcompanies,h

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

HPV cancer vaccine study demonstrates efficacy

JoeRaedle/GettyImagesVaccinesworkwelltopreventcancerscausedbythehumanpapillomavirus(HPV).Sowell,infa